Corticotropin-releasing factor (CRF) and the urocortins (UCN1, UCN2, and UCN3) belong to the CRF family of peptides and are the major regulators of the adaptive response to internal and external stresses. The actions of CRF and UCNs are mediated through two receptor subtypes: CRF receptor 1 (CRFR1) and CRFR2. Their physiological roles, among other functions, include the regulation of food intake and anxiety-like behavior. In this review, we describe the progress that has been made towards understanding how anxiety-and depression-like behavior and food intake are regulated by CRF, UCN1, UCN2, and UCN3.
Introduction
Corticotropin-releasing factor (CRF) is a 41-amino acid peptide that was isolated from the ovine hypothalamus and structurally characterized in 1981 (1) . CRF is widely expressed in the brain and in peripheral tissues of several species (2) (3) (4) . In the mammalian brain, CRF is highly expressed in the hypothalamus. Recently, several additional members of the CRF family have been identified: urocortin1 (UCN1) (5), UCN2 (6) , and UCN3 (7) . CRF and UCNs signal through two receptor subtypes: CRF receptor 1 (CRFR1) and CRFR2 (2) (Figure 1 ). Rat/human CRF binds with high affinity to CRFR1 and with a lower affinity to CRFR2 (3) .
The UCN1 gene was cloned from the rat midbrain in 1995, encoding a 40-amino acid peptide (5) . In the mammalian brain, UCN1 mRNA is highly expressed in the EdingerWestphal nucleus (8) . In addition, validated sites of brain UCN1 synthesis include the lateral superior olive, the supraoptic nucleus, the lateral hypothalamic area, and, caudally, several brainstem and spinal cord motoneuron nuclei (8) . In the periphery, UCN1 expression has been observed in adipose tissue (9) ; the heart (10-12); immune system (4, 13), including the spleen and thymus; the testes; the kidneys (14) ; the adrenal gland (15) ; and the skin (16, 17) . UCN1 is also present in the enteric nervous system of the duodenum, small intestine, and colon (8, 18) . UCN1 binds both CRFR1 and CRFR2 with higher affinities than CRF (19) .
The mouse UCN2 gene, discovered in 2001, encodes a 38-amino acid peptide (6) . Similar to UCN1, UCN2 mRNA is localized in the supraoptic nucleus and magnocellular subdivision of the paraventricular nucleus. Unlike UCN1, UCN2 also has marked expression in the arcuate nucleus of the hypothalamus (6) . A survey of peripheral rodent tissue for UCN2 gene expression revealed high levels in the skeletal muscles and skin, moderate levels in the lungs, stomach, adrenal glands, ovaries, brown fat, spleen and thymus, and lower or negligible levels in the testes, kidneys, liver, pancreas, white fat, intestine, heart, and aorta (20, 21) . In contrast to UCN1, UCN2 binds CRFR1 with low affinity (6), but unlike CRF, UCN2 binds with high affinity to CRFR2 (5, 6) .
The UCN3 gene was also identified in the mouse genome in 2001 (7) . Mouse UCN3 mRNA has been found in the brain, including the hypothalamus, amygdala, and brainstem (7) . UCN3 gene expression has also been detected in adipose tissue, the heart, skin, thyroid, adrenal glands, b cells of the pancreas, spleen, ovary, placenta, fetal membranes, kidneys, stomach, small intestine, colon, and rectum (22) . UCN3 selectively binds CRFR2 (7) . In contrast to UCN1, UCN3 binds to CRFR1 only with very low affinity (5, 7) .
In recent years, CRF and UCNs have been studied extensively. In this review, we describe the progress that has been made towards understanding how anxiety-and depressionlike behavior and food intake are regulated by CRF, UCN1, UCN2, and UCN3.
Effects of CRF family peptides on anxiety-like behavior CRF
CRF is the key central nervous system mediator of adaptation to stress (23) . Intracerebroventricular (ICV) administration of CRF induces anxiety-and depression-like behavior in rats or mice (24) (25) (26) (27) and can reproduce some features of irritable bowel syndrome, a stress-related disease, such as diarrhea (28) . By contrast, ICV administration of a CRF antagonist has anxiolytic-and antidepressant-like effects (29) and blocks the inhibition of gastric motor function that is induced by various stressors (30) . Interestingly, pretreatment with gonadotropin-releasing hormone (GnRH) agonists antagonizes CRF-induced anxiety-and depression-like behavior, indicating that GnRH negatively modulates CRFinduced behavioral effects (29) . Recently, it was reported that chronic stress increases CRF production in the raphe nucleus associated with decreased serotonin neurotransmission, depression, and anxiety (31) . By contrast, steroids increase serotonin effects in the brain by acting through the CRF system, which include decreased CRF transport to serotonin neurons and decreased CRFR1 expression, in conjunction with an increase in UCN1 transported caudally and an increase in CRFR2 and CRF-binding protein expression. As a result, the increase in serotonin action elevates mood, increases stress resistance, and decreases anxiety (32) . Nevertheless, CRF-deficient mice display normal behavioral responses to stressors (33) . This indicates the existence of developmental rescuing/compensation mechanisms other than the CRF system.
UCN1
Central UCN1 administration induces many neurochemical and behavioral changes. These include behavioral arousal properties in familiar environments and proconvulsant and anxiety-like effects. The anxiety-like properties of central UCN1 administration, mediated at least partly by CRFR1 receptors, have been shown in several conditions, including the open field, the plus maze, light/dark box, defensive withdrawal, and social interaction tests (34) (35) (36) (37) (38) (39) (40) . The endogenous anxiety-related roles of UCN1 remain uncertain, since Wang et al. reported that UCN1-deficient mice exhibit normal anxiety-like behavior and autonomic responses to stress (41), whereas another UCN1-deficient mouse model showed increased anxiety-like behavior in the plus maze and open field tests (42) . The endogenous anxiety-related roles of UCN1 also remain unclear.
UCN2
Unlike CRFR1 agonists, UCN2 does not induce malaise, arousal, or anxiety-like effects at the minimum central doses needed to reduce food intake in rats (6, 24, (43) (44) (45) (46) (47) (48) and even opposes the anxiety-like effects of CRF in the open field test (48, 49) . However, UCN2 can induce delayed anxiolytic-like effects under high-baseline anxiety conditions in the plus maze (48) . Furthermore, ICV administration of high doses of UCN2 to mice increases anxiety-like behavior in the plus maze, as well as acoustic startle responses (50, 51) . These results suggest that the effects of exogenous UCN2 on anxiety-like behavior are dependent on the dose of UCN2. UCN2-deficient mice do not exhibit altered anxiety-like behavior in the plus maze, light/dark box, or conditioned fear tests (52) . However, UCN1 and UCN2 double-deficient mice show a robust anxiolytic phenotype and modified serotonergic activity in anxiety circuits (53) . Moreover, female mice lacking UCN2 exhibit a significant increase in the basal daily rhythms of ACTH and corticosterone and a significant decrease in depression-like behavior (52).
UCN3
UCN3 does not increase anxiety-like behavior in the open field, the plus maze, light/dark box, social interaction, or defensive burying tests, under conditions in which CRFR1 agonists produce anxiety-like changes (49, 54) . In fact, ICV administration of UCN3 produces acute anxiolytic-like changes during the plus maze and light/dark box tests (49, 54) . Comprehensive behavioral phenotyping of UCN3-deficient mice did not show any alterations in measures of anxiety-or depression-related behaviors (55) .
Effects of CRF family peptides on the regulation of food intake CRF
In both light and dark phases, intraperitoneal (IP) administration of CRF suppresses food intake in mice. Food intake and body weight gain are inhibited by long-term administration (43, 56, 57) . The feeding-inhibitory action of IP administered CRF is similar to that of UCN2: more potent than UCN3 but weaker than UCN1 (57) . Most previous studies on the action of CRF on feeding behavior have demonstrated that CRF inhibits food intake when administered ICV to fasting rats or mice (6, (58) (59) (60) (61) . The feeding-inhibitory action of ICV administered CRF is more potent than that of UCN2 or UCN3, but it is weaker than that of UCN1 (61) . Effective ICV doses are lower than effective IP doses (57, 61) . Wildtype and CRF-deficient mice show similar intake of food pellets and sweetened milk (60) .
UCN1
Among the CRF family peptides, UCN1 has the most potent and prolonged inhibitory effect on decreasing food intake and body weight gain, when administered peripherally (56, 57, (62) (63) (64) . Repeated administration of UCN1 also significantly lowers blood glucose and decreases visceral fat weight in obese mice that are fed on a high-fat diet (57). Centrally Table 1 Effects of CRF family peptide deficiencies on feeding and anxiety-like behaviors in knockout mice.
Phenotype of deficient mice
≠, Stimulation of food intake or anxiety-like behaviors; -, no effects on food intake or anxiety-like behaviors; ?, not reported. administered UCN1 reduces food intake in rats or mice (43, 61, 65) . The feeding-inhibitory action of ICV administered UCN1 is the most potent of the CRF family peptides (61) . UCN1 infused into the fourth ventricle reduces intraoral sucrose solution intake, even in chronically maintained decerebrate rats, supporting a hindbrain-based mechanism of anorectic action for brainstem UCN1 (66) . Nevertheless, UCN1-deficient mice have normal basal feeding behavior (42) . This suggests the existence of compensatory mechanisms in deficient mice.
UCN2
In both light and dark phases, IP administration of UCN2 suppresses food intake in mice. Food intake and body weight gain are inhibited by long-term UCN2 administration (57). The feeding-inhibitory action of IP administered UCN2 is more potent than that of UCN3, but it is weaker than that of UCN1 and similar to that of CRF (57) . Central administration of UCN2 produces satiation-like changes in meal structure, with food intake reduced at UCN2 doses that do not induce signs of malaise (6, 22, 44-46, 61, 67, 68) . The feeding-inhibitory action of ICV administered UCN2 is weaker than that of UCN1 or CRF but similar to that of UCN3 (61) . Previous studies have shown that gastric vagal afferent activity is increased by peripheral administration of UCN2 (69) . The effect of UCN2 on the afferent activity of the gastric vagal nerve is similar to that of anorexigenic peptides CCK and peptide YY (PYY), and contrary to that of orexigenic peptide ghrelin (70, 71) . In addition, CRFR2 binding sites have been characterized on vagal afferent fibers (72) . UCN2-deficient mice exhibit normal spontaneous food intake (42, 52) . By contrast, UCN2 deficiency blunts the anorectic effects of fenfluramine, suggesting that UCN2 has a downstream role in satiating effects of serotonin (52).
UCN3
Only a few studies have assessed food intake alterations induced by UCN3. In both light and dark phases, IP administration of UCN3 suppresses food intake in mice. Food intake and body weight gain are inhibited by long-term UCN3 administration (57, 64, 73) . The feeding-inhibitory action of IP administered UCN3 is the weakest of the CRF family peptides (57) . ICV administration of UCN3 decreases food intake in high-fat diet-fed obese mice, as well as in lean mice. The feeding-inhibitory action of ICV administered UCN3 is weaker than that of UCN1 or CRF and similar to that of UCN2 (61) .
Perspective
Over the past decade, studies on the CRF family of peptides have revealed their close relation to physiological regulation of anxiety and feeding (Tables 1 and 2 ). The development of agonists and antagonists of their target receptors will contribute to a better understanding of the role of CRF-like signaling in various pathological states. Recent studies have shown that CRFR1 antagonists including antalarmin and CP-154526 decrease anxiety-and depression-like behaviors (4) and CRFR2 antagonists including antisauvagine-30 attenuate stress-induced anorexia (74, 75) . CRF family peptides and CRFRs are therefore promising targets for the treatment of obesity, diabetes, anxiety, and depression.
